NasdaqGS - Nasdaq Real Time Price USD
ImmunityBio, Inc. (IBRX)
Get in-depth analysis now
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.
6.13 -0.12 (-1.92%)
At close: February 2 at 4:00:02 PM EST
6.18 +0.05 (+0.81%)
After hours: 7:59:04 PM EST
Chart Range Bar
Loading chart for IBRX
Chart does not reflect overnight price.
News headlines ImmunityBio (IBRX) is gaining attention with its promising clinical trials and potential label expansions for its treatment ANKTIVA. Analysts have raised price targets, reflecting confidence in future sales growth, while the stock has recently experienced profit-taking after a significant rally.
ImmunityBio (IBRX) is gaining attention with its promising clinical trials and potential label expansions for its treatment ANKTIVA. Analysts have raised price targets, reflecting confidence in future sales growth, while the stock has recently experienced profit-taking after a significant rally.
Updated 12m ago · Powered by Yahoo Scout
- Previous Close
6.25 - Open
6.29 - Bid 6.09 x 3700
- Ask 6.17 x 3700
- Day's Range
5.93 - 6.75 - 52 Week Range
1.83 - 8.28 - Volume
24,115,653 - Avg. Volume
25,446,540 - Market Cap (intraday)
6.038B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.40 - Earnings Date (est.) Nov 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.80
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
immunitybio.comRecent News: IBRX
View More
Performance Overview: IBRX
Trailing total returns as of 2/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
IBRX
209.60%
S&P 500 (^GSPC)
1.91%
1-Year Return
IBRX
77.68%
S&P 500 (^GSPC)
15.49%
3-Year Return
IBRX
37.75%
S&P 500 (^GSPC)
66.91%
5-Year Return
IBRX
70.66%
S&P 500 (^GSPC)
82.33%
Earnings Trends: IBRX
View MoreAnalyst Insights: IBRX
View MoreStatistics: IBRX
View MoreValuation Measures
As of 1/29/2026
Market Cap
5.82B
Enterprise Value
6.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
64.80
Price/Book (mrq)
--
Enterprise Value/Revenue
78.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.89%
Return on Equity (ttm)
--
Revenue (ttm)
82.56M
Net Income Avi to Common (ttm)
-348.62M
Diluted EPS (ttm)
-0.40
Balance Sheet and Cash Flow
Total Cash (mrq)
257.81M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-230.46M
Compare To: IBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: IBRX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.